| Name | Bordetella Pertussis |
| Classes |
Immunotherapeutic Agent Vaccine |
| Diseases |
Immunological Disorder Whooping Cough |
Bangla
EnglishBordetella Pertussis
The Bordetella Pertussis vaccine is a biological product classified as a bacterial vaccine. It functions by stimulating the immune system to produce an immune response against Bordetella pertussis, the bacterium responsible for causing whooping cough (pertussis). The vaccine contains inactivated or subunit components of the bacterium, preparing the immune system to recognize and mount a defense against the actual pathogen.
The Bordetella Pertussis vaccine is indicated for active immunization against pertussis, especially in infants, children, adolescents, and adults.
-
Infants and Children (2 months to 6 years):
- The primary vaccination series typically consists of three doses administered at 2, 4, and 6 months of age.
- A booster dose is recommended around 15-18 months of age.
-
Adolescents (7 to 18 years) and Adults:
- A single booster dose is recommended around 11-12 years of age.
Common adverse reactions associated with the Bordetella Pertussis vaccine may include:
- Local reactions at the injection site (e.g., pain, redness, swelling)
- Fever
- Fussiness or irritability
- Hypersensitivity Reactions: The vaccine should be avoided in individuals with a known history of severe allergic reactions to any component of the vaccine.
- Febrile Illness: Administration of the vaccine should be postponed in individuals with moderate to severe febrile illness.
Contraindication
The Bordetella Pertussis vaccine is contraindicated in individuals with a history of severe allergic reactions to a previous dose of the vaccine or any of its components.
None known.
None known.